Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies


PALM BEACH GARDENS, Fla., Nov. 8, 2023 /PRNewswire/ -- Forward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, today announced a $50 million Series A financing. The financing was led by BVF Partners LP with participation from other leading life sciences investors RA Capital Management and OrbiMed.

Proceeds from the Series A financing will enable Forward to advance its portfolio of novel, small molecule immunology medicines towards clinical development. Forward Therapeutics is the first company to partner with Curie.Bio, a new model for venture capital in biotech focused on helping founders launch therapeutics companies.

"This Series A financing round is a significant milestone for Forward Therapeutics," said Toufike Kanouni, chief executive officer of Forward Therapeutics. "We are grateful to be supported by leading life sciences investors who recognize the potential of our novel therapies to impact the lives of millions of people living with chronic immunological and inflammatory conditions. We would also like to thank the Curie.Bio team for their support which helped create an efficient operational model and accelerate our pipeline."

"Our programs target key immunology nodes, aiming to reduce inflammation, promote healing and restore quality of life," said Ewan Taylor, chief scientific officer of Forward Therapeutics. "Our goal is to expand global patient access to high quality medicines. We appreciate our investors support to help achieve our vision."

About Forward Therapeutics
Forward Therapeutics is a biopharmaceutical company dedicated to transforming the treatment of chronic inflammatory disorders. The company is advancing a pipeline of novel, next-generation small molecule immune therapies. To learn more, please visit www.forward-tx.com and follow us on LinkedIn.

Media Contact:
1AB
Dan Budwick
[email protected]

SOURCE Forward Therapeutics


These press releases may also interest you

at 16:25
Claros Mortgage Trust, Inc. Reports First Quarter 2024 Results
Claros Mortgage Trust, Inc. (the "Company" or "CMTG") today reported its financial results for the quarter ended March 31, 2024. The Company's first quarter 2024 GAAP net loss was ($52.8 million), or ($0.39) per diluted share. Distributable Loss (a...

at 16:25
Crescent Energy Reports First Quarter 2024 Results
Crescent Energy Company ("Crescent" or the "Company") today announced financial and operating results for the first quarter of 2024. Crescent's earnings release and supplemental earnings presentation can be accessed via the Investor Relations...

at 16:22
Higginbotham and Barnard Insurance Group Form Powerful North Texas Team
Higginbotham, the largest independent insurance, financial and HR services firm headquartered in Texas and one of the top firms in the country, has brought on board Barnard Insurance Group of Wichita Falls, Texas. This move turns a friendly rivalry...

at 16:20
Williams Delivers Strong First-Quarter Results; Positioned to Hit Top Half of 2024 Financial Guidance Range
Williams today announced its unaudited financial results for the three months ended March 31, 2024. Business continues to outperform; solid execution on accretive acquisitions and organic growth driving immediate returns GAAP net income of $631...

at 16:20
Fabrinet Announces Third Quarter Fiscal Year 2024 Financial Results
Fabrinet , a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced its financial results for its third...

at 16:20
Cherry Hill Mortgage Investment Corporation Announces First Quarter 2024 Results
Cherry Hill Mortgage Investment Corporation ("Cherry Hill" or the "Company") today reported results for the first quarter 2024. First Quarter 2024 Highlights GAAP net income applicable to common stockholders of $9.7 million, or $0.32 per share....

More news about Business...


News published on and distributed by: